inHEART

The company was founded on over a decade of multidisciplinary research by cardiologists, radiologists, and computer scientists to address a significant clinical need. The founding team includes Dr. Hubert Cochet, a radiologist and expert in cardiac imaging, and Dr. Pierre Jaïs, a cardiologist and pioneer in cardiac catheter ablation. In October 2021, Todor Jeliaskov, an industry veteran with over 20 years of experience at companies like Siemens, GE Ultrasound, and NuVera Medical, was appointed CEO to drive commercial growth, with co-founder Jean-Marc Peyrat transitioning to the role of CTO.

inHEART’s core product is a software suite that analyzes preprocedural CT or MR images using a proprietary, AI-powered segmentation algorithm to generate highly detailed and interactive 3D models of a patient's heart. This digital twin provides unprecedented anatomical detail, including tissue characteristics and scar transmurality, which is not available with other tools. The software is designed for physicians and is delivered via a cloud-based platform. It integrates seamlessly with all major electroanatomic mapping (EAM) systems, allowing physicians to plan treatment strategies before a procedure and use the models for guidance during cardiac interventions. The primary clients are hospitals and cardiologists performing cardiac ablation procedures for arrhythmias like ventricular tachycardia (VT). Early clinical evaluations have shown that using the inHEART solution can reduce VT procedure times by up to 60% and lower arrhythmia recurrence rates.

The company has achieved significant regulatory milestones, including FDA 510(k) clearance in the U.S. and CE certification under the new MDR for the European market. In March 2024, inHEART received FDA clearance for its AI module that enables fully automated segmentation of CT images, significantly increasing the speed and efficiency of model creation. The company has raised a total of $15.2M over several funding rounds, including a Series B of $11 million in May 2024, to support commercial expansion in the US and EU and to develop new predictive software models for heart failure, sudden cardiac death, and cardio-embolic stroke.